Tag Archives: ALXN

Meet 5 Top Biotech Stocks Holding Up In Shaky Market

Everyone gets sick, and drastic health problems call for more drastic treatment. That’s partly why several top-rated biotech stocks in today’s IBD 50 list have held up well despite recent market pressue. Alexion Pharmaceuticals (ALXN), the fourth stock in today’s screen, develops treatments for neurological and other disorders. The company has two years of strong EPS and sales gains under its belt, driven by Soliris, its blockbuster drug that

Celgene, Alexion Both Beat And Raise, Stocks Rise

Big-cap biotechs Celgene (CELG) and Alexion Pharmaceuticals (ALXN) were both up in the stock market today after they beat analysts’ Q3 estimates and raised their guidance. Celgene’s Q3 earnings rose 24% over the year-earlier quarter to 97 cents a share, excluding one-time items, beating analysts’ estimates by 2 cents. Sales increased 18% to $1.98 billion, about $20 million above the Street’s forecast. Celgene guided full-year revenue at $7.6

Video: 3 Big Cap Biotechs Bucking Market Correction

Though the market is in a correction, there are several big cap medical stocks bucking the downtrend. IBD TV’s Alissa Williams breaks down the top three: Gilead Sciences (GILD), Actavis (ACT) and Alexion Pharmaceuticals (ALXN). Follow Alissa Williams on Twitter: @IBD_AWilliams .